Key factors
sym | ESPR |
exch | US |
MCap | 354.18M |
Beta | 0.822 |
EPS | -2.03 |
Div date | 0000-00-00 |
Yesterday
sym | ESPR |
exch | US |
close | 1.99 |
50 Day MA | 2.473 |
200 Day MA | 1.775 |
52 Week High | 3.4 |
52 Week Low | 0.7 |
Target Price | 7.41 |
Market Cap Mln | 354.18 |
Share statistics
Shares Outstanding | 189.40M |
Shares Float | 184.02M |
Percent Institutions | 39.06 |
PercentInsiders | 0.45 |
SharesShort | 19.92M |
Short Ratio | 3.13 |
Shares Short Prior Month | 17.66M |
Short Percent | 12.02 |
Short Percent Float | 12.02 |
Income
Revenue TTM | 116.33M |
Revenue Per Share TTM | 1.128 |
Quarterly Revenue Growth YOY | 71.39 |
Gross Profit TTM | -70.4M |
EBITDA | -155.3M |
Diluted Eps TTM | -2.03 |
earning
Operating Margin TTM | -1.31 |
PEGRatio | -4.78 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Current Year | -0.4 |
EPS Estimate Next Quarter | -0.04 |
EPS Estimate Next Year | 0.05 |
Earnings Share | -2.03 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2013-06-11 |
Last Split Factor | 1:6 |
business
Enterprise Value Ebitda | -3.86 |
Enterprise Value Revenue | 4.985 |
Book Value /share | -3.84 |
Price Book MRQ | 74.88 |
Price Sales TTM | 3.404 |
ProfitMargin | -1.79 |
ReturnOnAssetsTTM | -0.42 |
ReturnOnEquityTTM | -2.60 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Codes
ISIN | US29664W1053 |
CIK | 1434868 |
Code | ESPR |
CUSIP | 29664W105 |
Employer Id Number | 26-1870780 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 1.028 |
Full Time Employees | 240.0 |
IPODate | 2013-06-26 |
International Domestic | Domestic |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Esperion Therapeutics Inc |
Address | 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 |
Country Name | USA |
Phone | 734 887 3903 |
Web URL | https://www.esperion.com |
Logo URL | /img/logos/US/ESPR.png |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.